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Monitoring the population effectiveness of 
pneumococcal conjugate vaccination in the Finnish 
national vaccination programme
Finland introduced the 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) into the 
national infant vaccination programme in September 2010. This document describes the surveillance 
system and analysis methods for continuous monitoring of the population impact of the national vac-
cination programme (NVP), as implemented by the National Institute for Health and Welfare (THL). 
THL is a Finnish research and development institute operating under the Ministry of Social Affairs and 
Health, which was formed on 1 January 2009, with the merger of the National Public Health Institute of 
Finland (KTL) and the National Research and Development Centre for Welfare and Health (STAKES).
The background and rationale for the effectiveness evaluation are presented in Section 2. In Section 
3, the existing data sources and surveillance methods for pneumococcal disease are described, including 
the IPD incidence. The fourth Section elaborates on the enhanced surveillance methods put in place 
after the introduction of NVP, including plans for analysis. Section 5 deals with reporting issues.
1 Introduction 
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2.1  Rationale
Pneumococcal conjugate vaccines (PCVs) have been shown to reduce burden of Streptococcus pneumo-
niae diseases, not only through direct protection provided to the vaccinated children but also through 
indirect protection of the unvaccinated children and adults. In the U.S., where infants have been vac-
cinated with the 7-valent PCV (PCV7, Prevenar®, Pfizer) since 2000 (and with PCV13 since 2010), the 
incidence of Invasive Pneumococcal Disease (IPD) has decreased considerably in all age groups. In 
addition, hospitalization rates for pneumonia have also markedly decreased after introduction of PCV7 
into NVP in the U.S., for children younger than 2 years but also for adults aged 18-39 years. However, 
the decreases in IPD due to the vaccine serotypes has in some regions been accompanied by increases 
in IPD caused by non-vaccine serotypes, especially serotype 19A. 
Continuous monitoring of pneumococcal diseases and evaluation of the population impact of PCVs are an 
essential part of all vaccination programs after implementation. As Finland has recently introduced PCV for 
children, THL will monitor closely the epidemiology of IPD, but also occurrence of pneumonia and acute otitis 
media (AOM) through national health registers to assess the overall public health benefits of the program. 
Finland is especially suitable for surveillance due to long tradition of established health registers 
for the whole country, universal use of unique and life-long Personal Identity Code for each Finnish 
citizen, expected high coverage of NVP, and public health care system equally accessible for each citizen. 
2.2  pneumococcal vaccination in Finland
According to vaccine sales data obtained from the Finnish pharmacy records, the private sector use of  PCVs 
(PCV7 licensed in February 2001, PCV10 (Synflorix by GSK) in March 2009, and PCV13 (Prevenar 13 by 
Pfizer) in December 2009), has been minimal since their licensure  (an average of 100 doses/month). The 
use of 23-valent polysaccharide vaccine in the adult and elderly population has been similarly infrequent.
Finland introduced PCV10 (Synflorix, GSK) in NVP for a period of two years in September 2010 
after public tender, which is currently repeated every two years. The target group is all children born at 
or after June 1, 2010. The vaccination schedule is 2 primary doses at the ages of 3 and 5 months and a 
booster dose at 12 months of age. The vaccines are administered concomitantly with other NVP vac-
cinations in Finland. No catch-up vaccination schedules are used. For children with risk factors for 
pneumococcal disease PCV administration for older children up to 4 years of age is also recommended 
followed by one polysaccharide dose after 2 years of age.
In May 2009, before PCV was introduced to the NVP, THL started the Finnish Invasive Pneumococ-
cal disease vaccine effectiveness (FinIP) trial, in co-operation with 80% of Finnish health care centers and 
GSK, to evaluate the overall effectiveness of PCV10 in the population. The FinIP trial was designed as a 
community-randomized, double-blind trial and will enable the evaluation of the overall effectiveness of the 
PCV10 against IPD by measuring the effects both among vaccinated children (direct and indirect effects, i.e. 
total effects) and among unvaccinated children and adults (indirect effects i.e. herd effects). Two thirds of the 
study clusters use PCV10 and one third of the clusters are control areas, in which the children receive either 
the hepatitis B vaccine (children aged 6 weeks to 11 months at enrolment) or hepatitis A vaccine (children 
aged 12 to 18 months at enrolment). Effectiveness of immunization according to a 2-dose or 3-dose primary 
schedule, followed by a booster dose, will also be assessed in the randomized study setting among children 
enrolled <7 months of age. In addition to IPD, the trial will evaluate total and indirect vaccine impact on the 
incidence of hospital-diagnosed pneumonia, as well as the vaccine’s impact on tympanostomy tube placement 
and outpatient prescriptions of antimicrobial agents. All outcome data for the FinIP trial will be collected 
from the national registers. 
Since approximately 50,000 children are participating and vaccinated in the FinIP trial, this needs 
to be taken into account, and utilized when possible, in the evaluation of the overall NVP impact; see 
Section 4 for further details.
2 Background
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3.1  Register data sources for pneumococcal disease
The following national registers will be used in the evaluation of PCV NVP:
•	 National Infectious Disease Register, maintained by KTL/THL since 1995
o  Invasive pneumococcal disease (incl. serotyping and antimicrobial susceptibility)
•	 National Care Register maintained by STAKES/THL since 1994
o  Hospital-diagnosed pneumonia (ICD-10 coded)
o  Tympanostomy tube placement (performed in public health care)
•	 Social Insurance Institution register 
o  Tympanostomy tube placement (performed in private health care) (since 1964)
o  Outpatient prescriptions of antimicrobial agents (since 1995, since 2006 in the current form)
The primary data source for the NVP PCV evaluation is the National Infectious Disease register 
(NIDR) which is a population-based and laboratory-based surveillance system. It includes all IPD 
isolates reported by the Finnish clinical microbiology laboratories. A case of IPD, defined by detection 
by culture either from blood or cerebrospinal fluid, is typically recorded into the NIDR within 2 weeks 
of the date of sample collection. Duplicate reports of cases within 3 months are merged into episodes at 
THL. The reference laboratories at THL provide serotyping and antimicrobial susceptibility data for the 
pneumococcal isolates. Until 2009, serotyping was performed at THL laboratory in Oulu, where latex 
agglutination and counterimmunoelectrophoresis and quellung reaction (when needed) were used. 
Since 2010, serotyping has been performed at THL laboratory in Helsinki, where PCR-based seroty-
ping and quellung reaction (when needed) are used. Determination of antimicrobial susceptibility for 
penicillin, erythromycin, tetracycline, levofloxacin, clindamycin and ceftriaxone is performed at THL 
laboratory in Turku for all IPD isolates using the agar dilution method, usually within 2 to 6 months of 
the receipt of the isolate. Additionally, the FiRe project (FiRe - Finnish Study Group for Antimicrobial 
Resistance), coordinated by THL annually collects clinically performed, aggregated antimicrobial sus-
ceptibility data. Further information is available at  http://www.finres.fi/index.php?id=12. The FiRe data 
also include other than IPD isolates, e.g. middle ear discharge specimens from children with AOM. 
The availability and usefulness of these data in the evaluation of the PCV programme will be explored.
Other clinical syndromes potentially caused by pneumococcus are, among others, pneumonia and 
AOM. The National Care Register (HILMO) contains all outpatient and inpatient diagnoses (ICD10) 
given at Finnish hospitals. The HILMO has been operational since 1994, and has included outpatient 
visits since 1999. In accordance with the current legislation, the data accumulates to the HILMO in 
yearly batches. The data is available approximately 9 months after the new year.
Social Insurance Institution maintains a register that has been operational since 1964 with mul-
tiple changes and adaptations to current Finnish laws. Expanding data has been collected on national 
insurance reimbursements including drug prescriptions since 1995. From 2006 onwards all prescription 
medications bought from pharmacies are included in this register. Between 1995 and 2006 only purcha-
ses of drugs that were covered by the national insurance reimbursement were included in the register. 
Thus, e.g. cheap antibiotics with lower expense than the reimbursement level were not included in the 
register before 2006. Delay for data collection purposes is minimum 6 weeks.
3 Existing surveillance systems and   
 data sources
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3.2  Invasive pneumococcal disease
Compared to other European countries, the incidence of IPD in Finland is relatively high, yet conside-
rably lower than in the U.S. before the PCV introduction. Table 1 shows the recent IPD frequencies by 
age group and calendar year in Finland. The average incidence in age groups 0 to 1, 2 to 64, and over 
65-year-olds during 2004-2010 were, respectively, 60, 11, and 32 cases per 100,000 person-years.
table 1: IpD frequencies by age and calendar year
Calendar year  0-1 years 2-64 years 65 and over total 
2004 70 440 239 749 
2005 73 435 230 738 
2006 82 394 271 747 
2007 78 418 295 791 
2008 65 533 328 926 
2009 62 498 295 855 
2010 61 471 304 836 
3.3  NVp vaccination coverage in Finland
Based on bi-annual coverage surveys conducted by the Department of Vaccination and Immune Pro-
tection, the uptake of PCV is expected to be over 95% in the NVP. Infant and childhood vaccines are 
administered in the municipal well-baby clinics, which are attended 8 times by 12 months of age by 
practically all children born in Finland. The total population of Finland is 5.3 million with mainly Cau-
casian origin. The annual birth cohort is approximately 60 000.
In addition to bi-annual coverage surveys, THL is in the process of implementing an online nation-
wide vaccination register. This register is expected to become operational during 2012. Vaccination 
register will be utilized in the follow-up of PCV vaccine coverage. 
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4 Enhanced surveillance and analysis plan
4.1  Follow-up of breakthrough cases of invasive pneumococcal disease
Enhanced surveillance of all IPD reports for children born after 1 June, 2010, i.e. eligible for the natio-
nal PCV vaccination programme, has been set up. A notification of any IPD case occurring in this 
age-group is sent online from the NIDR to the Department of Vaccination and Immune protection. 
Subsequently, vaccination information is verified from the medical records at primary health care. The 
serotyping of IPD isolates from children is prioritized at THL reference laboratory.
4.2  populations under surveillance
The total (i.e. the sum of direct and indirect) effectiveness of the NVP will be evaluated among children 
born after 1st of June 2010. Indirect effectiveness will be evaluated in those born before 1st of June 2007, 
stratified by age. Those born between June 2007 and June 2010 have largely been eligible for the FinIP 
study, and will mainly be evaluated in the trial setting. 
Further risk group stratifications, such as based on low birth weight, will be subsequently performed. 
However, due to relatively small birth cohort in Finland, it is expected that sufficient power for the eva-
luation of total effectiveness in any subgroup analysis is achieved only after several years of surveillance 
(see also Table 1).
Figure 1 depicts the assumed increase in vaccination coverage for children under 2-years of age.
Figure 1.  pCV NVp effectiveness surveillance designs in Finland based on estimated national coverage of pCV 
  vaccinations in children under 2 years of age
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2008 2009 2010 2011 2012 
Calendar time, month and year 
Before PCV introduction                                             FinIP trial vaccinations (2/3 PCV)                         PCV NVP started 9/2010 for 3-month-old children 
Commercial vaccine use                                              Local variation due to participation,                       no catch-up vaccinations 
                                                                                     randomization and enrolment success                    95% constant coverage expected 
Before                                     Transition/FinIP trial                      NVP implementation                            NVP full coverage 
Trial unblinded 2012 
Parallel study design in  
addition to before-after: 
Arm 1: FinIP PCV clusters (50 %) 
Arm 2: FinIP control clusters (25 %) 
Arm 3: Non-FinIP areas (25 %) 
Assessment before FinIP unblinding 
Before-After study design  
on national level: 
1) Before FinIP and NVP (before 6/2009) 
2) FinIP trial phase (2009 to 2010) 
3) PCV NVP (fall 2010 onwards) 
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4.3  pneumococcal disease outcomes to be monitored
The following outcomes will be used for the population effectiveness:
•	 Invasive pneumococcal disease
•	 Hospital-diagnosed pneumonia
•	 Tympanostomy tube surgery
•	 Outpatient treatment with antimicrobial agents
Because of the low specificity of other outcomes than IPD, and delays of data accumulation in other 
registers than NIDR, the primary focus will be on IPD. The rates of IPD will be further stratified accor-
ding to the serotypes and –groups covered by the PCV in the NVP (currently: PCV10 types, PCV10-
related, and non-PCV10 types) and antimicrobial resistance. Other outcome evaluations are conditional 
on acceptance of relevant research permissions.
4.4  Comparison of the rates of pneumococcal diseases 
The rates of disease endpoints will be compared both between and within calendar time (i.e before/after 
and in parallel time, see also Figure 2). Calendar time evaluation will be performed in three phases:
1) Before the start of the FinIP trial
2) FinIP trial phase
3) After implementation of PCV NVP
After the unblinding of the FinIP trial in 2012, three distinct areas in Finland can also be identified for 
parallel comparison:
1) Area in the FinIP trial where PCV10 was administered (50% of the population)
2) Area in the FinIP trial where control vaccine was administered (25% of the population)
3) Area not included in the FinIP trial (25% of the population)
4.5  Additional studies
An annual report on the population effectiveness of the National PCV vaccination programme will be 
published in Finnish and English on the public website of THL by May/June each year, beginning from 
2012. Because of the register data delays, this report will include data extracted from NIDR and KELA 
registers up to the year prior to the reporting year, and data extracted from HILMO up to two years 
prior to the reporting year. The primary focus will be on the investigation of changes in the incidence 
of IPD, with a special emphasis on the total and indirect effectiveness, including serotype distribution 
and antimicrobial resistance.
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5 Reporting
An annual report on the population effectiveness of the National PCV vaccination programme will 
be published in Finnish and English on the public website of THL by May/June each year, beginning 
from 2012. This report will include data extracted from NIDR and KELA registers up to the year prior 
to the reporting year, and data extracted from HILMO up to two years prior to the reporting year. The 
primary focus will be on the investigation of changes in the incidence of IPD, with a special emphasis 
on the total and indirect effectiveness.
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